Literature DB >> 25422260

Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy.

Ryan P Westergaard1, Lauren J Stockman2, Heather A Hyland3, Sheila M Guilfoyle2, John J Fangman3, James M Vergeront2.   

Abstract

New recommendations for birth cohort screening for hepatitis C virus (HCV) infection and the development of new, highly effective antiviral medications are expected to increase the demand for HCV treatment. In the past, antiviral therapy for HCV was almost exclusively prescribed by specialists in the field of gastroenterology and infectious diseases, meaning that people living in rural areas that are underserved by specialists may have poor access to treatment. We investigated the number and geographic distribution of medical providers who actively prescribed direct acting antiviral drugs for hepatitis C in Wisconsin during 2012. Using public health surveillance data and a state-wide prescription drug database, we found that there was 1 treatment provider for every 340 residents known to be living with HCV. However, 51 of 72 Wisconsin counties had no providers who provided HCV treatment in 2012.Scaling up antiviral treatment to address the epidemic of hepatitis C efficiently and equitably will require strategies to increase the number of treatment providers in rural communities. Providing education, training, and support to the primary care workforce serving rural communities should be considered a potentially effective and efficient approach to preventing future HCV-related illness.
© The Author(s) 2014.

Entities:  

Keywords:  access to care; efficiency; medications; primary care; rural health

Mesh:

Substances:

Year:  2014        PMID: 25422260      PMCID: PMC4442083          DOI: 10.1177/2150131914560229

Source DB:  PubMed          Journal:  J Prim Care Community Health        ISSN: 2150-1319


  11 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  Notes from the field : hepatitis C virus infections among young adults--rural Wisconsin, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-05-18       Impact factor: 17.586

3.  Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2013-09-03       Impact factor: 25.391

4.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

5.  Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

Authors:  James A Morrill; Melissa Shrestha; Richard W Grant
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

6.  A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.

Authors:  Christopher E McGowan; Ali Monis; Bruce R Bacon; Josep Mallolas; Fernando L Goncales; Ioannis Goulis; Fred Poordad; Nezam Afdhal; Stefan Zeuzem; Teerha Piratvisuth; Patrick Marcellin; Michael W Fried
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Initial implementation and evaluation of a Hepatitis C treatment clinical decision support system (CDSS): a nurse practitioner-driven quality improvement initiative.

Authors:  L Fathauer; J Meek
Journal:  Appl Clin Inform       Date:  2012-09-19       Impact factor: 2.342

9.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

Review 10.  The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Authors:  N H Afdhal; S Zeuzem; R T Schooley; D L Thomas; J W Ward; A H Litwin; H Razavi; L Castera; T Poynard; A Muir; S H Mehta; L Dee; C Graham; D R Church; A H Talal; M S Sulkowski; I M Jacobson
Journal:  J Viral Hepat       Date:  2013-11       Impact factor: 3.728

View more
  15 in total

Review 1.  Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.

Authors:  Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

2.  Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers.

Authors:  Shashi N Kapadia; Kristen M Marks
Journal:  Clin Ther       Date:  2018-07-05       Impact factor: 3.393

3.  Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers.

Authors:  Rena Fox
Journal:  Dig Dis Sci       Date:  2016-12       Impact factor: 3.199

4.  Commentary on Fraser et al. (2018): Evidence base for harm reduction services-the urban-rural divide.

Authors:  Kathryn E Lancaster; Carlos D Malvestutto; William C Miller; Vivian F Go
Journal:  Addiction       Date:  2018-01       Impact factor: 6.526

5.  Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity.

Authors:  Shashi N Kapadia; Carrie D Johnston; Kristen M Marks; Bruce R Schackman; Erika G Martin
Journal:  J Public Health Manag Pract       Date:  2019 May/Jun

Review 6.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

7.  Training to Cure-Implementing a Hepatitis C Clinic Curriculum in Primary Care Residency Training.

Authors:  Yihan Yang; Jeffrey M Luk; Andre N Sofair; Siyuan Ma; Yanhong Deng; Joseph Canterino
Journal:  Med Sci Educ       Date:  2020-10-14

8.  Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?

Authors:  Ping Du; Xi Wang; Lan Kong; Jeah Jung
Journal:  Telemed J E Health       Date:  2020-09-02       Impact factor: 3.536

9.  Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017.

Authors:  Ping Du; Xi Wang; Lan Kong; Thomas Riley; Jeah Jung
Journal:  Am J Prev Med       Date:  2020-11-19       Impact factor: 5.043

10.  A Telementoring Program and Hepatitis C Virus Care in Rural Patients.

Authors:  Ping Du; Xin Yin; Lan Kong; Jeah Jung
Journal:  Telemed Rep       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.